Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Relmacabtagene Autoleucel in combination with the Sintilimab regimen for the treatment of relapsed/refractory B-cell lymphoma

Trial Details

NCT ID
NCT07077512
Phase
PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Mantle Cell Lymphoma Lymphoma
Interventions
  • Autoleucel (Relmacabtagene Autoleucel)
  • Sintilimab (PD-1 inhibitor)
Locations (sample)
  • Guangzhou, China|23.11667,113.25
  • Guangzhou, China|23.11667,113.25
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • The patient must be aware of and voluntarily sign the informed consent form (ICF).
  • Aged between 18 and 70 years, both male and female.
  • Pathologically diagnosed with DLBCL, FL, or MCL, with histological confirmation of CD19 positivity (immunohistochemistry or flow cytometry, with fl…
  • The patient must be willing to receive regorafenib and sintilimab treatment and be deemed suitable for this treatment by the investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Mantle Cell Lymphoma Lymphoma Trials on Trialify →